FUNDACAO GIMM - GULBENKIAN INSTITUTE FOR MOLECULAR MEDICINE

Their core work

The Gulbenkian Institute for Molecular Medicine (iMM) is a Lisbon-based biomedical research centre focused on understanding the molecular mechanisms of disease — from infection and immunity to neurological disorders and cancer. They conduct translational research spanning parasitology, neuroscience, RNA biology, and nanomedicine, with a strong track record in ERC-funded fundamental science. Their work bridges basic molecular discovery with preclinical applications, including drug development for CNS diseases, nanoparticle-based therapeutics, and digital health endpoints for neurodegenerative conditions.

What they specialise in

How they've shifted over time

In 2015–2018, iMM focused heavily on institutional capacity building (EXCELLtoINNOV, TwinnToInfect) and establishing its research identity in immunity, infection, and synaptic neuroscience. From 2019 onward, the institute shifted decisively toward translational applications — nanomedicine, drug design for CNS diseases, digital health endpoints, and AI-driven imaging — while maintaining its immunology base. The recent projects show a clear move from descriptive biology toward therapeutic and technological outputs.

iMM is evolving from a fundamental biomedical research institute toward applied translational work integrating nanomedicine, AI, and digital health tools — making them increasingly relevant for industry partnerships in drug delivery and diagnostics.

How they like to work

iMM leads slightly more than it follows, coordinating 9 out of 17 projects, which signals strong project management capacity and scientific leadership. With 200 unique partners across 25 countries, they operate as a well-connected hub rather than a closed network. Their mix of small focused ERC grants (as coordinator) and large multi-partner consortia (as participant) suggests they are comfortable both driving their own agenda and contributing specialist expertise to broader efforts.

iMM has collaborated with 200 distinct partners across 25 countries, reflecting a broad European network with particular strength in building bridges between Southern and Northern European institutions. Their Widening Participation projects (EXCELLtoINNOV, TwinnToInfect) were specifically designed to expand Portugal's integration into top-tier European research networks.

What sets them apart

iMM sits at an unusual intersection: a Portuguese research centre with the scientific clout to win multiple ERC grants (3 Consolidator, 1 Synergy) while also running Widening Participation projects that strengthen Southern European research ecosystems. Their combination of deep neuroscience and immunology expertise with growing capabilities in nanomedicine and digital health makes them a versatile partner for both fundamental and translational consortia. For industry, they offer preclinical molecular research capacity with direct relevance to drug delivery, diagnostics, and neurotech.

Highlights from their portfolio

• ArpComplexity
  Largest single grant (EUR 3.2M ERC Synergy), investigating fundamental cell biology through Cryo-EM — signals world-class structural biology capability.
• NOVIRUSES2BRAIN
  Ambitious coordinator-led project (EUR 2.1M) designing a universal antiviral drug that crosses the blood-brain barrier — direct pharmaceutical industry relevance.
• IDEA-FAST
  Part of a major IMI-scale consortium developing digital biomarkers for neurodegenerative diseases, positioning iMM at the intersection of neuroscience and digital health.